The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
Herbert Aaron Eradat
Research Funding - Gilead Sciences
Steven E. Coutre
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Jacqueline Claudia Barrientos
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Kanti Roop Rai
Research Funding - Gilead Sciences
Charles Michael Farber
Research Funding - Gilead Sciences
Peter Hillmen
Research Funding - Gilead Sciences
Jeff Porter Sharman
Research Funding - Gilead Sciences
Paolo Ghia
Research Funding - Gilead Sciences
Bertrand Coiffier
Research Funding - Gilead Sciences
Jan Andrzej Walewski
No relevant relationships to disclose
Zwi N. Berneman
Research Funding - Gilead Sciences
Susan Mary O'Brien
Research Funding - Gilead Sciences
Jennifer R. Brown
No relevant relationships to disclose
Sissy Peterman
Employment or Leadership Position - Gilead Sciences
Research Funding - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Thomas Michael Jahn
Employment or Leadership Position - Gilead Sciences
Paula Cramer
Research Funding - Gilead Sciences
Michael J. Hallek
Research Funding - Gilead Sciences